Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adrenaline (epinephrine), quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; water for injections; hydrochloric acid - for the emergency treatment of anaphylactic reactions to insect stings through immediate self administration by individuals with a history of hypersensitivity to insect stings. epipen and epipen jr. are designated as emergency supportive therapy only and are not a replacement or substitute for subsequent medical or hospital care, nor are they intended to supplant insect venom hyposensitization. indications as at 17 june 2003: for the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, drugs or other allergens for the emergency treatment of anaphylactic reactions to insect stings through immediate self administration by individuals with a history of hypersensitivity to insect stings. epipen and epipen jr. are designated as emergency supportive therapy only and are not a replacement or substitute for subsequent medical or hospital care, nor are they intended to supplant insect venom hyposensitization. indications as at 17 june 2003: for the emergency treatment of anaphylax

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adrenaline (epinephrine), quantity: 0.5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium chloride; hydrochloric acid - for the emergency treatment of anaphylactic reactions to insect stings through immediate self administration by individuals with a history of hypersensitivity to insect stings. adrenaline mylan and adrenaline jr mylan are designated as emergency supportive therapy only and are not a replacement or substitute for subsequent medical or hospital care, nor are they intended to supplant insect venom hyposensitization. indications as at 17 june 2003: for the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, drugs or other allergens.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adrenaline (epinephrine), quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; water for injections; hydrochloric acid - for the emergency treatment of anaphylactic reactions to insect stings through immediate self administration by individuals with a history of hypersensitivity to insect stings. adrenaline mylan and adrenaline jr mylan are designated as emergency supportive therapy only and are not a replacement or substitute for subsequent medical or hospital care, nor are they intended to supplant insect venom hyposensitization. indications as at 17 june 2003: for the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, drugs or other allergens.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 25000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions

Australia - inglés - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

artex limited - hyaluronidase 1500 [iu] - powder for injection - 1500 iu - active: hyaluronidase 1500 [iu] - latest regulatory activity

Bangladés - inglés - DGDA (Directorate General of Drug Administration)

techno drugs ltd. - hyaluronidase - injection - 150 iu/vial

Estados Unidos - inglés - NLM (National Library of Medicine)

janssen biotech, inc. - daratumumab (unii: 4z63yk6e0e) (daratumumab - unii:4z63yk6e0e), hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - darzalex faspro is indicated for the treatment of adult patients with multiple myeloma: - in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. - in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. - in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. - in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. - in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. - in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have receive

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - hylenex recombinant is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. hylenex recombinant is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs. hylenex recombinant is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. hylenex recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in hylenex recombinant. a preliminary skin test for hypersensitivity to hylenex recombinant can be performed. the skin test is made by an intradermal injection of approximately 0.02 ml (3 units) of a 150 unit/ml solution. a positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20 to 30 minutes and accompanied by localized itching. transient vasodilation at the site of the test, i.e., erythema, is not a positive reaction. discontinue hylenex recombinant if sensitization occurs. pregnancy category c. in an em

Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

janssen pharmaceutical k.k. - daratumumab(genetical recombination); vorhyaluronidase alfa(genetical recombination) - injection